$奥锐特(SH605116)$ $诺和诺德(NVO)$ #司美格鲁肽# #替尔泊肽# 才是真正在走向神坛！#减肥神药能开发出多少适应症#Post hoc analyses explored the impact of semaglutide across an array of conditions, including obstructive sleep apnoea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic risk factors, and other obesity-related comorbiditiesObesity is a chronic disease that can cause many complications in the body, contributing to serious comorbidities and broader health issuesAcross these analyses, findings explore the impact of treatment with semaglutide on obstructive sleep apnoea (OSA), asthma-related adverse outcomes, cardiometabolic risk factors, and other obesity-related complications.Novo Nordisk is presenting post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association® (ADA), highlighting data regarding the impact of semaglutide across weight-related conditions.Multiple post hoc analyses were of the SELECT study, the pivotal study which led to an indication to reduce the risk of MACE in adults with obesity or overweight and established cardiovascular disease, along with diet and exercise1-2,7Two of the post hoc analyses demonstrated semaglutide use was associated with a reduction of asthma-related adverse outcomes and improvements in systolic blood pressure for those with uncontrolled hypertension and overweight or obesity, respectively$礼来(LLY)$